Lacosamide Fresenius Kabi (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, which stabilizes neuronal membranes and reduces hyper‑excitability. It also binds to CRMP‑2, a protein involved in neuronal development, contributing to its antiepileptic activity without affecting the fast inactivation phase of sodium channels.

The specific dose of Lacosamide Fresenius Kabi is determined by the prescribing clinician based on the patient’s clinical condition, age, renal and hepatic function, and concomitant therapies. Healthcare professionals tailor the regimen to achieve optimal seizure control while minimizing adverse effects.

The safety of lacosamide in pregnancy and lactation has not been definitively established. It is classified as having an unknown pregnancy category, so clinicians must weigh potential benefits against possible risks and discuss options with the patient. Breastfeeding decisions should also consider drug excretion in milk.

To request Lacosamide Fresenius Kabi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Lacosamide differs from many traditional antiepileptics by selectively enhancing slow sodium‑channel inactivation, offering a distinct mechanism that may be beneficial for patients who have not responded to drugs acting on fast inactivation. It is often compared with agents like carbamazepine or phenytoin, which have broader sodium‑channel effects and different interaction profiles.

Lacosamide Fresenius Kabi must be stored at 2‑8 °C in a refrigerator, protected from light. The solution should not be frozen or shaken vigorously. Keep the vial in its original packaging until use to maintain stability and sterility.

The medication is supplied as an injectable solution for intravenous infusion. Healthcare professionals administer it under controlled conditions, typically as a slow infusion over several minutes, following the dosing instructions provided by the prescriber and adhering to aseptic technique.

Serious risks include cardiac conduction abnormalities such as PR‑interval prolongation, which can lead to arrhythmias, as well as rare but severe skin reactions (e.g., Stevens‑Johnson syndrome), respiratory depression when combined with other CNS depressants, and potential suicidal thoughts. Prompt medical evaluation is required if these occur.

Patients with known hypersensitivity to lacosamide or any component of the formulation should avoid its use. Individuals with significant cardiac conduction disorders (e.g., second‑degree AV block) or uncontrolled severe hepatic impairment should not receive the drug without specialist assessment.